{
  "docId": "019de076-b7ca-70fb-95b8-5a74e3aefffe",
  "docSlug": "5062b9a9257606648ea145bccd66e04d",
  "documentTitle": "Nuvalent | Investor Presentation Deck | 41 slides",
  "authorId": "nuvalent",
  "authorName": "Nuvalent",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-01-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 34,
  "pageCount": 41,
  "prevPage": 33,
  "nextPage": 35,
  "slideType": "appendix_data",
  "function": "analyze_data",
  "density": "dense",
  "nDataPoints": 24,
  "notes": "Data as of 13 Sep 2022. N=35 patients.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-b7ca-70fb-95b8-5a74e3aefffe/34",
  "deckHref": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe",
  "deckJsonHref": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe.json",
  "deckAnchorHref": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe#slide-34",
  "components": [
    {
      "bbox": {
        "h": 0.25,
        "w": 0.32,
        "x": 0.08,
        "y": 0.34
      },
      "kind": "list",
      "text": "No DLTs; No treatment-related SAEs; No AEs leading to dose reduction or discontinuation; No treatment-related dizziness",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "402c6d4e-f7f3-4e2e-9f43-80abb07d0fe9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.72,
        "x": 0.058,
        "y": 0.85
      },
      "kind": "source-note",
      "text": "Data as of 13 Sep 2022, for patients treated by 01 Sep 2022. AE, adverse event; ALT, Alanine aminotransferase; AST, Aspartate aminotransferase; DLT, dose-limiting toxicity; SAE, serious adverse event. a Including oedema and oedema peripheral. Source: Drilon A. et al., EORTC-NCI-AACR 2022.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4882a9f5-808f-4362-86f5-541ef71115de",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.52,
        "x": 0.398,
        "y": 0.275
      },
      "kind": "table",
      "text": "Treatment-Related Adverse Events (TRAEs) in >1 Patient. All Treated Patients (N = 35). Table rows: Fatigue, Nausea, ALT increased, AST increased, Oedema, Myalgia.",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "71932d27-2fe6-4e7f-ad8b-8cde3e121384",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.84,
        "x": 0.058,
        "y": 0.113
      },
      "kind": "title",
      "text": "Preliminary Safety Profile: Favorable and Consistent with the Highly ROS1-Selective, TRK-Sparing Design of NVL-520",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2e779900-817c-4c01-a2ee-15a494e49330",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}